Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Our study showed that riluzole plus mFOLFOX6/bevacizumab is well tolerated in patients with metastatic colorectal cancer and may have clinical activity in patients whose disease is resistant to FOLFOX.
Authors
- John L. Hays (ORCID: https://orcid.org/0000-0003-3140-8677)
- Anne M. Noonan (ORCID: https://orcid.org/0000-0001-8083-8492)
- Beiyuan Liang (ORCID: https://orcid.org/0009-0009-0953-5638)
- Joo Young Na (ORCID: https://orcid.org/0000-0002-4533-7358)
- Wayne Miles (ORCID: https://orcid.org/0000-0002-2054-5206)
- Lai Wei (ORCID: https://orcid.org/0000-0002-7248-3828)
- Jing J. Wang (ORCID: https://orcid.org/0009-0005-5145-1156)
- Pannaga Malalur (ORCID: https://orcid.org/0000-0002-9222-4321)
- Arjun Mittra (ORCID: https://orcid.org/0000-0001-9572-3495)
- Ashish Manne (ORCID: https://orcid.org/0000-0003-2356-5162)
- Rifat T. Elkhatib
- Ning Jin (ORCID: https://orcid.org/0000-0002-6689-4671)
- Evan H. Zhang (ORCID: https://orcid.org/0009-0001-6591-3973)
- Liwei Yan
- Mitch A. Phelps (ORCID: https://orcid.org/0000-0002-1615-5280)
- Shafia Rahman (ORCID: https://orcid.org/0000-0003-4751-0852)
- Sameek Roychowdhury (ORCID: https://orcid.org/0000-0002-8297-3038)
- Hayden Storts (ORCID: https://orcid.org/0009-0004-1945-4536)
- Nicole Abbott (ORCID: https://orcid.org/0009-0006-0316-2701)
- Chunjie Li (ORCID: https://orcid.org/0009-0006-2503-4401)
- Misbah Khan (ORCID: https://orcid.org/0000-0002-9063-5477)
- Vedat Yildiz (ORCID: https://orcid.org/0000-0002-3069-7502)
- Kasey Hill
Institutions
- University of Michigan (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University Wexner Medical Center (US)
- The Ohio State University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3964
- Citations
- 2
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 2.09